Hancock Whitney Corp Has $16.74 Million Position in Cencora, Inc. (NYSE:COR)

Hancock Whitney Corp lowered its holdings in Cencora, Inc. (NYSE:COR) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,364 shares of the company’s stock after selling 251 shares during the quarter. Hancock Whitney Corp’s holdings in Cencora were worth $16,738,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. New Millennium Group LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC acquired a new position in Cencora in the second quarter valued at about $30,000. Concord Wealth Partners bought a new stake in Cencora during the third quarter worth about $30,000. LRI Investments LLC bought a new stake in Cencora during the first quarter worth about $31,000. Finally, SYSTM Wealth Solutions LLC bought a new stake in Cencora during the second quarter worth about $36,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR opened at $245.02 on Monday. The company has a fifty day moving average price of $233.22 and a two-hundred day moving average price of $231.70. The firm has a market capitalization of $48.28 billion, a PE ratio of 32.63, a P/E/G ratio of 1.63 and a beta of 0.44. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $251.56. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Analyst Ratings Changes

Several research analysts have recently commented on COR shares. Bank of America reissued a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. UBS Group raised their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Leerink Partners decreased their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.